Phase I clinical study of quelamycin

Area of Science:

• Oncology
• Pharmacology
• Clinical Medicine

Background:

• Adriamycin derivatives are crucial in cancer therapy.
• Quelamycin is a newly synthesized triferric derivative of adriamycin.
• Understanding the safety and efficacy profile of novel chemotherapeutics is essential.

Purpose of the Study:

• To evaluate the safety and preliminary efficacy of quelamycin in a Phase I clinical trial.
• To determine the dose-limiting toxicity of quelamycin.
• To assess the objective response rates in patients with non-small cell lung carcinoma and metastatic sarcoma.

Main Methods:

• A Phase I clinical study was conducted.
• Twenty-one patients with non-small cell lung carcinoma (19) and metastatic sarcoma (2) were enrolled.
• Patients received single-dose intravenous quelamycin, with dose escalation to determine toxicity.

Main Results:

• All patients experienced acute toxicity, including fever, flushing, hypertension, body aches, tremors, and confusion.
• Eight patients with pre-existing rhythm disturbances developed cardiotoxicity (tachycardia, arrhythmias, branch block).
• Dose-limiting hematologic toxicity occurred at 125 mg/m2 IV; objective responses were observed in 3/19 lung cancer patients and 1/2 sarcoma patients.

Conclusions:

• Quelamycin, an adriamycin derivative, demonstrates potential therapeutic interest.
• The current dosing schedule results in excessive acute and cardiotoxicity.
• Further studies are warranted to optimize the quelamycin administration schedule and reduce side effects.